New Zealand decision relating to a number of respiratory products

3 February 2016

Following a consultation last December, New Zealand’s Pharmaceutical Management Agency PHARMAC is today announced the approval of agreements with the local subsidiaries of Germany’s Boehringer Ingelheim and the UK’s GlaxoSmithKline (LSE: GSK) involving a number of respiratory products.

The proposal was approved as consulted on. In summary, from March 1, 2016, the effect of the decision is that:

Two new long-acting muscarinic antagonists (LAMAs) will be funded;
One of the LAMAs, Incruse Ellipta (umeclidinium), supplied by GSK, will be funded without a Special Authority (an endorsement that the patient has been diagnosed with COPD by spirometry will apply);
Three new combination long-acting muscarinic antagonists/long-acting beta-adrenoceptor agonists (LAMA/LABAs) will be funded, subject to restrictions;
One new inhaled cortical steroid (ICS)/LABA will be funded;
Changes to the LAMA Special Authority renewal criteria will be made;
Price and subsidies will be reduced for certain currently listed ICS/LABA and LABA products;
Confidential rebates will apply to all products except the Volumatic spacer; and
The price of Volumatic will be reduced.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK